Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.

Anfal AlsadhanJean CheungMichael GulrajaniErika M GaglionePia NiermanAhmed HamdyRaquel IzumiElena BibikovaPriti PatelClare SunTodd CoveySarah E M HermanAdrian Wiestner

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Higher BTK occupancy was achieved with twice daily over once daily dosing, resulting in deeper and more sustained inhibition of BCR signaling.

Keyphrases

tyrosine kinase
chronic lymphocytic leukemia
physical activity
acute lymphoblastic leukemia
newly diagnosed